RayKnowChina Research Map
Shortlist0

ShenzhenPeking Union Medical College / Chinese Academy of Medical Sciences

Cancer Hospital CAMS – Shenzhen

中国医学科学院肿瘤医院深圳医院

Listed for 6 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Cancer Hospital CAMS – Shenzhen

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌7 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌7 papers led
  3. Hepatocellular carcinoma肝细胞癌6 papers led1 open trial led
  4. Stomach cancer胃癌3 papers led1 open trial led
  5. Osteosarcoma骨肉瘤1 paper led
  6. Ewing sarcoma尤文肉瘤0 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 7 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 222025

8 hospitals in Shenzhen for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07325539

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shenzhen

  2. Recruiting
    Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07362979

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesDongguan, Guangzhou, Shenzhen, Zhanjiang

  3. Recruiting
    Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07661771

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan

  4. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  5. Recruiting
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06455410

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseImaging & AI
Departments in papersRadiation oncologyRadiology / nuclear medicine
Papers it led7
  1. Application of multidimensional diffusion-weighted magnetic resonance imaging in nasopharyngeal carcinoma: a prospective study.2026Clinical radiology
  2. Clinical benefits of enhanced 3D-NEVERview sequence in MRI simulation for nasopharyngeal carcinoma patients received radiotherapy.2025BMC cancerFree full text
  3. Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. Loco-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma with chemotherapy and immunotherapy: A real-world retrospective study from two cancer centers.2024Head & neck
  5. Optimizing the cumulative cisplatin dose for concurrent chemoradiotherapy beneficiaries among elderly nasopharyngeal carcinoma patients: a real world study.2024Scientific reportsFree full text
  6. Evaluation of plan robustness on the dosimetry of volumetric arc radiotherapy (VMAT) with set-up uncertainty in Nasopharyngeal carcinoma (NPC) radiotherapy.2022Radiation oncology (London, England)Free full text
  7. DVH Prediction for VMAT in NPC with GRU-RNN: An Improved Method by Considering Biological Effects.2021BioMed research internationalFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05385926Lead (inferred)Phase 2Start 2022-05
  2. Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07362979Study sitePhase 2Start 2026-03
  3. LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPCRecruitingNCT07325539Study sitePhase 2Start 2026-01
  4. Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal CarcinomaRecruitingNCT07661771Study sitePhase 3Start 2026-07
  5. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  6. GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Study sitePhase 2Start 2024-06
  7. Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.Active, not recruitingNCT07201337Study sitePhase 3Start 2025-11
  8. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06712888Study sitePhase 3Start 2025-02
More papers found outside PubMed (not counted)24
  1. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncologyarticle
  2. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  3. CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma2025Holistic Integrative Oncologyarticle
  4. Safety and Efficacy of Local Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma with Immunochemotherapy: Systematic Review and Meta-Analysis2025International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  6. A random forest model to predict the efficacy of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma based on the data from the KL167-II-05-CTP study.2024Journal of Clinical Oncologyconference-abstract
  7. Cross-Technique Transfer Learning to Predict the Dose Distribution for Radiotherapy Planning Based on a Limited Sample Size2024International Journal of Radiation Oncology*Biology*Physicsarticle
  8. Long-Term Treatment Outcomes and Late Toxicity between Childhood and Adult Nasopharyngeal Carcinoma in the Era of IMRT2024International Journal of Radiation Oncology*Biology*Physicsarticle
  9. Neoadjuvant Chemotherapy plus Tislelizumab Followed by Adjuvant Tislelizumab for Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial2024International Journal of Radiation Oncology*Biology*Physicsarticle
  10. Significance of Longitudinal Epstein-Barr Virus DNA Combined with Tumor Response for Risk Stratification and Therapy Adaption in Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  11. A Rare Case of EBV-positive Inflammatory Follicular Dendritic Cell Sarcoma of the Iliac Bone2023Research Squarepreprint
  12. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  13. Combining Radiotherapy with Chemotherapy and Immunotherapy as First-Line Treatment for De Novo Metastatic Nasopharyngeal Carcinoma: A Dual-Center Retrospective Analysis2023International Journal of Radiation Oncology*Biology*Physicsarticle
  14. Investigating transfer learning to improve the deep-learning-based segmentation of organs at risk among different medical centers for nasopharyngeal carcinoma2023Frontiers in Physicsarticle
  15. More Efficient Auto-Segmentation Framework Using Patient-Specific Information for CBCT-Guided Adaptive Radiotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  16. Prediction of Anatomical Presentation during Radiotherapy of Nasopharyngeal Carcinoma Using GAN-LSTM for Plan Adaption Decision2023International Journal of Radiation Oncology*Biology*Physicsarticle
  17. Progress in the comprehensive treatment of nasopharyngeal carcinoma: a review for risk-stratified management strategies2023Holistic Integrative Oncologyarticle
  18. Prospective Efficacy of Two Cycles Toripalimab Plus Induction Chemotherapy in T4 or N3 Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective and Mechanistic Study2023International Journal of Radiation Oncology*Biology*Physicsarticle
  19. The Short-Term Efficacy and Safety of Induction Chemotherapy Combined with PD-1 Inhibitor or Anti-EGFR in Locoregionally Advanced Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  20. MRI-Identified Multidimensional Nodal Features: Predict Survival and Concurrent Chemotherapy Benefit for Stage II Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  21. Potential Metastatic Distance of Lymph Nodes in Different Metastatic Patterns for Nasopharyngeal Carcinoma: Implications for Caudal Border of Elective Nodal Target Volume Delineation2022International Journal of Radiation Oncology*Biology*Physicsarticle
  22. Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.2021Journal of Clinical Oncologyconference-abstract
  23. Prognostic Significance of Tumor Infiltrating Lymphocytes (TILs) and Programmed Cell Death-Ligand 1 (PD-L1) in Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle
  24. Stereotactic Body Radiation Therapy for the First-Line Comprehensive Treatment of Oligometastatic Nasopharyngeal Carcinoma: A Prospective, Single-Arm, Phase II Trial2021International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 7 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 0020242025: 222025

3 hospitals in Shenzhen for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentSurgeryImmunotherapy
Departments in papersRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led7
  1. Recurrence patterns and adjuvant therapy strategies in patients with esophageal squamous cell carcinoma who achieved pathological complete response after neoadjuvant immunochemotherapy: A high-volume retrospective study.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. Current status and perspectives of esophageal cancer: a comprehensive review.2025Cancer communications (London, England)Free full text
  3. Case Report: The huge esophageal displacement: a case of dramatic esophageal interfraction motion during neoadjuvant chemotherapy and immunotherapy.2025Frontiers in immunologyFree full text
  4. circHIPK3 regulates cell proliferation and migration by sponging microRNA-124 and regulating serine/threonine kinase 3 expression in esophageal squamous cell carcinoma.2022BioengineeredFree full text
  5. Deubiquitinase USP8 increases ID1 stability and promotes esophageal squamous cell carcinoma tumorigenesis.2022Cancer letters
  6. LHX2 Enhances the Malignant Phenotype of Esophageal Squamous Cell Carcinoma by Upregulating the Expression of SERPINE2.2022GenesFree full text
  7. Upregulation of OATP1A2 in human oesophageal squamous cell carcinoma cells via the HDAC6-GCN5/PCAF-H3K9Ac axis.2021Xenobiotica; the fate of foreign compounds in biological systems
Chinese-language papers (not in the count)1
  1. [Research progress and challenges of neoadjuvant therapy for esophageal squamous cell carcinoma].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status3
  1. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  2. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  3. CCRT With Itraconazole in Locally Advanced Squamous Esophageal CancerStatus unknownNCT04481100Study sitePhase 2Start 2020-10
More papers found outside PubMed (not counted)57
  1. 1570P A phase I clinical trial of 5T4-antibody NK cell conjugation (IBR854 Injection) in patients with advanced solid tumor2025Annals of Oncologyarticle
  2. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  3. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncologyarticle
  4. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagusarticle
  5. 396P Overexpression of CKS1B in tumor causes CD8+ T cell exhaustion via persistent tumor-antigen stimulation and impaired immune selection2025Immuno-Oncology Technologyarticle
  6. A Multi-Dimensional Deep Ensemble Learning Model Predicts Pathological Response and Treatment Outcomes to Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Using Pretreatment CT Images: A Multicenter, Retrospective Cohort 2025International Journal of Radiation Oncology*Biology*Physicsarticle
  7. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Researchconference-abstract
  8. An organ-preserving strategy in patients with esophageal squamous cell carcinoma treated with immunochemotherapy.2025Journal of Clinical Oncologyconference-abstract
  9. Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from an open-label, multicenter phase II trial (2025Journal of Clinical Oncologyconference-abstract
  10. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncologyarticle
  11. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncologyconference-abstract
  12. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  13. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncologyarticle
  14. 179P Personalized minimal residual disease profiling predicts prognosis in esophageal carcinoma undergoing definitive radiotherapy2024Annals of Oncologyarticle
  15. 502P A novel miRNA pair biomarker of miR-1180-3p|miR-505-3p for predicting neoadjuvant chemoradiotherapy survival in esophageal squamous cell carcinoma: A multicenter study in China2024Annals of Oncologyarticle
  16. AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study.2024Journal of Clinical Oncologyconference-abstract
  17. Abstract 2010: TRIM27 Interacts with KLF12 to regulate L1CAM expression, influencing cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma2024Cancer Researchconference-abstract
  18. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  19. Efficacy and Safety of the Combination of Tislelizumab with Chemoradiotherapy in Oligorecurrence Esophageal Squamous Cell Carcinoma: A Prospective Phase II Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  20. Efficacy and safety of the combination of tisleizumab with chemoradiotherapy in oligorecurrence esophageal squamous cell carcinoma: A prospective phase II study.2024Journal of Clinical Oncologyconference-abstract
  21. Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as the first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC): An open-label, multicenter phase II trial– Upda2024Journal of Clinical Oncologyconference-abstract
  22. Multimodality Deep Learning Radiomics Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy2024International Journal of Radiation Oncology*Biology*Physicsarticle
  23. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Squarepreprint
  24. Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: A prospective phase II trial.2024Journal of Clinical Oncologyconference-abstract
  25. Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligometastasis at Initial Diagnosis2024International Journal of Radiation Oncology*Biology*Physicsarticle
  26. Right vs Left Thoracic Approach for Esophageal Adenocarcinoma2024Difficult decisions in surgery: an evidence-based approachbook-chapter
  27. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.2024Journal of Clinical Oncologyconference-abstract
  28. “Pacific” Modality in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis of a Real-World Multicenter Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  29. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  30. Abstract 2594: Alcohol drinking inhibits NOTCH-PAX9 signaling in esophageal squamous epithelial cells2023Cancer Researchconference-abstract
  31. Chemoradiotherapy Combined with Nab-Paclitaxel plus Cisplatin in Patients with Locally Advanced Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Study2023International Journal of Radiation Oncology*Biology*Physicsarticle
  32. Data from Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression2023Venue not listedother
  33. Data from Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression2023Venue not listedother
  34. Data from CstF64-Induced Shortening of the BID 3′UTR Promotes Esophageal Squamous Cell Carcinoma Progression by Disrupting ceRNA Cross-talk with ZFP36L22023Venue not listedother
  35. Data from CstF64-Induced Shortening of the BID 3′UTR Promotes Esophageal Squamous Cell Carcinoma Progression by Disrupting ceRNA Cross-talk with ZFP36L22023Venue not listedother
  36. Identification of lymphophilic subtype in resectable esophageal squamous cell carcinoma using genetic signatures from large-scale genomic repertoires2023Research Squarepreprint
  37. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncologyconference-abstract
  38. P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study2023Annals of Oncologyconference-abstract
  39. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncologyconference-abstract
  40. 121TiP Prospective, single arm, phase II clinical trial of pembrolizumab combined with neoadjuvant chemoradiotherapy and surgery for locally advanced upper esophageal squamous cell carcinoma2022Immuno-Oncology Technologyarticle
  41. 92P Neoadjuvant multimodality RX including immunotherapy for highly selective unresectable locally advanced esophageal squamous cell carcinoma (NEXUS): A prospective, single-arm, phase II trial2022Immuno-Oncology Technologyarticle
  42. A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.2022Journal of Clinical Oncologyconference-abstract
  43. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  44. Elevated Expression of The RNA-Binding Protein IGF2BP1 Enhances The Mrna Stability and Translation Efficiency of INHBA to Promote The Invasion and Migration of Esophageal Squamous Cancer Cells2022Research Squarepreprint
  45. MO21-4 Microbial biomarker and epidemiological factor to identify esophageal squamous cell carcinoma and precancerous lesions2022Annals of Oncologyarticle
  46. Neoadjuvant Chemoradiotherapy vs. Neoadjuvant Chemotherapy for the Treatment of Esophageal Squamous Cell Carcinoma: A Stabilized Inverse Probability of Treatment Weighting Analysis2022International Journal of Radiation Oncology*Biology*Physicsarticle
  47. Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma.2022Journal of Clinical Oncologyconference-abstract
  48. Survival Benefit of Surgery in Patients with Clinical T4 Esophageal Cancer Responded to Neoadjuvant Chemoradiotherapy/Radiotherapy2022International Journal of Radiation Oncology*Biology*Physicsarticle
  49. The Prognostic Value of Circulating Tumor DNA during Post-Radiotherapy Surveillance in Esophageal Squamous Cell Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  50. mRNA expression pattern study of esophageal basaloid squamous cell carcinoma.2022Journal of Clinical Oncologyconference-abstract
  51. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  52. 1435TiP Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial2021Annals of Oncologyarticle
  53. Abstract 1981: TGF-β induced PLEK2 promotes metastasis and chemoresistance in ESCC by up-regulation of LCN22021Cancer Researchconference-abstract
  54. Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection2021International Journal of Radiation Oncology*Biology*Physicsarticle
  55. Elevated Expression of the RNA-Binding Protein IGF2BP1 Enhances the Mrna Stability and Translation Efficiency of INHBA to Promote the Invasion and Migration of Esophageal Squamous Cancer Cells2021Research Squarepreprint
  56. Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.2021Journal of Clinical Oncologyconference-abstract
  57. Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 6 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025

8 hospitals in Shenzhen for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07192848

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital CAMS – ShenzhenShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgery & liver transplantRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine
Papers it led6
  1. ELF3-AS1 promotes the carcinogenesis of hepatocellular carcinoma cells by inhibiting miR-98-5p/CPSF4 axis.2026Nucleosides, nucleotides & nucleic acids
  2. Preoperative circulating tumor cells indicate microvascular invasion and dynamical detection indicate the early recurrence of hepatocellular carcinoma.2025BMC cancerFree full text
  3. The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysis.2025Frontiers in immunologyFree full text
  4. A Super-Assembled Synergistically Nanoplatform AP@ZIF-8Pt for Hepatocarcinoma Therapy.2025International journal of nanomedicineFree full text
  5. Causal relationships among gut microbiota, plasma metabolites, and hepatocellular carcinoma: A mediation Mendelian randomization study.2025MedicineFree full text
  6. Emergency versus delayed hepatectomy following transarterial embolization in spontaneously ruptured hepatocellular carcinoma survivors: a systematic review and meta-analysis.2022World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Adebrelimab + Apatinib in Advanced HCC Post-Systemic TherapyNot yet recruitingNCT07192848Lead (inferred)Phase 2Start 2025-09
  2. the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaStatus unknownNCT05408221Study sitePhase 2/Phase 3Start 2022-11
  3. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Study sitePhase 2Start 2021-01
  4. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Study sitePhase 1/Phase 2Start 2019-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 3 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.03%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

7 hospitals in Shenzhen for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Registry
    NCT06776770

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital CAMS – ShenzhenShenzhen

  2. Recruiting
    Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07689851

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsPeritoneal spread & advanced diseaseChemotherapy & combined treatment
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

23 hospitals in Shenzhen for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Papers it led1
  1. Knockdown of LncRNA DICER1-AS1 arrests the cell cycle, inhibits cell proliferation, and induces cell apoptosis by regulating CDC5L nuclear transfer in osteosarcoma.2023Connective tissue research
Chinese-language papers (not in the count)1
  1. Extraskeletal Ewing sarcoma of thyroid gland: A case report.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Shenzhen for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Chinese-language papers (not in the count)1
  1. Extraskeletal Ewing sarcoma of thyroid gland: A case report.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中国医学科学院肿瘤医院深圳医院

Cancer Hospital CAMS – Shenzhen

深圳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Cancer Hospital & Shenzhen Hospital; Cancer Hospital Chinese Academy of Medical Sciences; Shenzhen Hospital; National Cancer Center/Cancer Hospital& Shenzhen Hospital; National Cancer Center/Cancer Hospital & Shenzhen Hospital; Shenzhen Hospital of Cancer Hospital; Cancer hospital Chinese academy of medical science; Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Center

Suggest a correctionDownload the data